Variables | Pre-operative ED | Post-operative ED | Post-operative incontinence | ||||||
---|---|---|---|---|---|---|---|---|---|
OR | 95%CI | p value | OR | 95%CI | p value | OR | 95%CI | p value | |
TT (normal vs low) | 0.525 | 0.322–0.856 | 0.010* | 1.580 | 0.491-5.076 | 0.443 | 1.566 | 0.540–4.540 | 0.409 |
FT (normal vs low) | 0.824 | 0.433–1.570 | 0.557 | 0.332 | 0.180–0.612 | < 0.001* | 0.885 | 0.368–2.128 | 0.784 |
Age(continuous) | 1.107 | 1.074–1.141 | < 0.001* | 1.118 | 1.076-1.161 | < 0.001* | 1.039 | 1.003-1.076 | 0.034* |
BMI (continuous) | 0.968 | 0.918–1.021 | 0.232 | 0.973 | 0.911–1.039 | 0.493 | 1.033 | 0.961–1.111 | 0.377 |
Diabetes (presence vs absence) | 0.846 | 0.519–1.378 | 0.502 | 1.073 | 0.573–2.008 | 0.826 | 1.095 | 0.543–2.210 | 0.800 |
Hypertension (presence vs absence) | 0.784 | 0.457–1.347 | 0.379 | 0.760 | 0.404–1.428 | 0.393 | 1.115 | 0.549–2.265 | 0.764 |
Coronary heart disease (presence vs absence) | 1.443 | 0.803–2.594 | 0.221 | 0.732 | 0.336–1.596 | 0.433 | 0.813 | 0.346–1.909 | 0.634 |
Smoke (presence vs absence) | 2.450 | 1.477–4.064 | 0.001* | 0.720 | 0.352-1.470 | 0.366 | 0.794 | 0.370–1.705 | 0.555 |
Alcohol (presence vs absence) | 1.197 | 0.768–1.867 | 0.427 | 1.102 | 0.617–1.969 | 0.742 | 0.800 | 0.421–1.522 | 0.496 |
PSA (≥10 ng/ml vs < 10 ng/ml) | 1.511 | 0.997–2.289 | 0.052 | 0.806 | 0.495–1.311 | 0.384 | 0.842 | 0.486–1.459 | 0.539 |
Proportion of free-PSA (≥ 0.16 vs < 0.16) | 1.333 | 0.878–2.023 | 0.177 | 0.899 | 0.530–1.527 | 0.694 | 0.931 | 0.523–1.656 | 0.807 |
Clinical Tumor stage (T2a vs T3) | 0.479 | 0.244–0.939 | 0.032* | ||||||
Clinical (T2b vs T3) | 0.949 | 0.558–1.613 | 0.847 | ||||||
Clinical (T2c vs T3) | 0.655 | 0.400–1.072 | 0.092 | ||||||
Biopsy Gleason Score (6 vs 8 or higher) | 0.829 | 0.470–1.462 | 0.518 | ||||||
Biopsy Gleason Score (7 vs 8 or higher) | 0.823 | 0.523–1.294 | 0.398 | ||||||
Surgical approach (open vs laparoscopic) | 0.616 | 0.385–0.986 | 0.044* | 0.972 | 0.580-1.628 | 0.913 | |||
NVB preserve(presence vs absence) | 1.479 | 0.890–2.456 | 0.131 | 1.069 | 0.621–1.840 | 0.809 | |||
Pathological Tumor stage (T2a vs T3) | 0.806 | 0.350–1.859 | 0.614 | 1.614 | 0.634–4.112 | 0.316 | |||
Pathological Tumor stage (T2b vs T3) | 1.096 | 0.553–2.171 | 0.794 | 1.700 | 0.793–3.645 | 0.173 | |||
Pathological Tumor stage (T2c vs T3) | 1.177 | 0.638–2.196 | 0.602 | 1.274 | 0.617–2.629 | 0.513 | |||
Final Gleason Score (6 vs 8 or higher) | 0.555 | 0.280–1.100 | 0.092 | 1.134 | 0.513–2.510 | 0.756 | |||
Final Gleason Score (7 vs 8 or higher) | 0.466 | 0.263–0.826 | 0.009* | 0.976 | 0.514–1.852 | 0.940 | |||
Lymph node status (N- vs N+) | 2.242 | 0.638–7.877 | 0.208 | 3.202 | 0.393–26.079 | 0.277 | |||
Lymph node status (Nx vs N+) | 3.344 | 0.962–11.623 | 0.058 | 2.864 | 0.349–23.489 | 0.327 | |||
PSM (presence vs absence) | 0.722 | 0.304–1.716 | 0.460 | 1.005 | 0.364–2.773 | 0.993 |